Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.56 |
| ▸ | MET | P08581 | 14/20 | 0.56 |
| ▸ | FLT1 | P17948 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 11/20 | 0.44 |
| ▸ | TEK | Q02763 | 11/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.43 |
| ▸ | LCK | P06239 | 7/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | LYN | P07948 | 2/20 | 0.43 |
| ▸ | FGR | P09769 | 1/20 | 0.43 |
| ▸ | MST1R | Q04912 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6315836 | 0.92 | KDR (0.54) | KDRMETFLT1AURKATEK | |
| SCHEMBL6307758 | 0.90 | KDR (0.58) | KDRMETFLT1AURKATEK | |
| SCHEMBL6308192 | 0.88 | KDR (0.57) | KDRMETFLT1AURKATEK | |
| SCHEMBL5768513 | 0.86 | KDR (0.49) | KDRMETFLT1AURKATEK | |
| SCHEMBL6309400 | 0.85 | KDR (0.49) | KDRMETFLT1AURKATEK | |
| SCHEMBL6310032 | 0.83 | KDR (0.54) | KDRMETFLT1AURKATEK | |
| SCHEMBL14953390 | 0.82 | KDR (0.59) | KDRMETFLT1MST1RBTK | |
| SCHEMBL14953388 | 0.82 | KDR (0.59) | KDRMETFLT1MST1RBTK | |
| SCHEMBL6747147 | 0.81 | KDR (0.54) | KDRMETFLT1MST1RBTK | |
| SCHEMBL6315261 | 0.80 | KDR (0.51) | KDRMETFLT1AURKATEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660503-A1 | NAPHTHALENE CARBOXAMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050070508-A1 | Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents | AGOURON PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2005021553-A1 | NAPHTHALENE CARBOXAMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070508-A1 | Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents | CCNA1, CCNA2, CCNT1 | KDR 30/4885MET 3202/4885FLT1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.